FDA pauses Swedish diabetes company's phase III trial plans

The share price of biotech company Diamyd Medical is falling after the the US Food and Drug Administration postponed its planned phase III trial because of several outstanding questions.

Photo: Diamyd Medical / PR

The US Food and Drug Administration (FDA) has put Diamyd Medical's planned phase III trial under a 'partial clinical hold'.

This means that the FDA hasn't been able to approve all parts of the Swedish company's application to begin the study. A lack of sufficient information concerning Diamyd's drug candidate is the cause, the FDA reports, according to a press release from Diamyd Medical.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs